Spots Global Cancer Trial Database for 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Official Title: A Prospective, Open-Label, Single-Arm, Multi-center Study to Evaluate the Diagnostic Efficacy and Safety of 68Ga-PSMA-11 PET/CT or PET/MRI in Patients With Biochemical Recurrent Prostate Cancer
Study ID: NCT05847348
Study Description
Brief Summary: This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Xiangya Hospital Central South University, Changsha, , China
Nanfang Hospital Southern Medical University, Guangzhou, , China
Fudan University Shanghai Cancer Center, Shanghai, , China
West China Hospital of Sichuan University, Sichuan, , China
Wuhan Union Hospital, Wuhan, , China
Zhongnan Hospital of Wuhan University, Wuhan, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
